Posted by Michael Wonder on 08 Jun 2026
US FDA approves Pfizer’s Hympavzi for the treatment of two additional haemophilia A or B patient populations with significant medical need
8 June 2026 - Pfizer today announced that the US FDA has approved an expanded indication for Hympavzi (marstacimab-hncq) to include the treatment of patients with haemophilia A or B 12 years and older with inhibitors and paediatric patients (ages 6 to 11 years) with or without inhibitors.
Hympavzi is now indicated in the US for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and paediatric patients 6 years of age and older with haemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors, or haemophilia B (congenital factor IX deficiency) with or without factor IX inhibitors.
